0001493152-24-009684.txt : 20240312 0001493152-24-009684.hdr.sgml : 20240312 20240312170519 ACCESSION NUMBER: 0001493152-24-009684 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240306 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240312 DATE AS OF CHANGE: 20240312 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Imunon, Inc. CENTRAL INDEX KEY: 0000749647 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 521256615 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15911 FILM NUMBER: 24743185 BUSINESS ADDRESS: STREET 1: 997 LENOX DRIVE STREET 2: SUITE 100 CITY: LAWRENCEVILLE STATE: NJ ZIP: 08648 BUSINESS PHONE: (609) 896-9100 MAIL ADDRESS: STREET 1: 997 LENOX DRIVE STREET 2: SUITE 100 CITY: LAWRENCEVILLE STATE: NJ ZIP: 08648 FORMER COMPANY: FORMER CONFORMED NAME: Celsion CORP DATE OF NAME CHANGE: 20071121 FORMER COMPANY: FORMER CONFORMED NAME: CELSION CORP DATE OF NAME CHANGE: 19980515 FORMER COMPANY: FORMER CONFORMED NAME: CHEUNG LABORATORIES INC DATE OF NAME CHANGE: 19920703 8-K 1 form8-k.htm
false 0000749647 0000749647 2024-03-06 2024-03-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 6, 2024

 

Imunon, Inc.

(Exact name of registrant as specified in its Charter)

 

Delaware   001-15911   52-1256615

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

997 Lenox Drive, Suite 100, Lawrenceville, NJ   08648-2311
(Address of principal executive offices)   (Zip Code)

 

(609) 896-9100

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act

 

Title of each class   Trading symbol(s)   Name of each exchange on which registered
Common stock, par value $0.01 per share   IMNN   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On March 6, 2024, Dr. Corinne Le Goff, Pharm.D., informed the Board of Directors (the “Board”) of Imunon, Inc. (the “Company”) of her resignation from her position as President and Chief Executive Officer of the Company and from the Board, effective as of March 15, 2024. Dr. Le Goff’s resignation was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.

 

The Company is conducting a search for Dr. Le Goff’s successor as Chief Executive Officer. Michael H. Tardugno, the Company’s Executive Chairman, and Chief Executive Officer prior to Dr. Le Goff, will assume day-to-day leadership of the Company until such successor is named and will continue in his role directing Company strategy.

 

Item 7.01 Regulation FD Disclosure.

 

On March 12, 2024, the Company issued a press release announcing the resignation of Dr. Le Goff. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Securities Act, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits

 

Exhibit   Description
     
99.1   Press Release, dated March 12, 2024.
104   Cover Page Interactive Data File (embedded within Inline XBRL document).

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  IMUNON INC.
     
Dated: March 12, 2024 By: /s/ Jeffrey W. Church
    Jeffrey W. Church
    Executive Vice President and Chief Financial Officer

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

IMUNON Announces Leadership Change

 

Executive Chairman to lead day-to-day operations, active search underway for CEO successor.

 

Timing of upcoming milestones for key programs remains unchanged.

 

LAWRENCEVILLE, N.J. (March 12, 2024) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that Dr. Corinne Le Goff, Pharm.D. has resigned as President and Chief Executive Officer, and from the Board of Directors, to pursue another business opportunity. Dr. Le Goff’s resignation will be effective as of March 15, 2024. Michael H. Tardugno, the Company’s Executive Chairman, and Chief Executive Officer prior to Dr. Le Goff, will assume day-to-day leadership until a successor is named and will continue in his role directing Company strategy.

 

“IMUNON has the bench strength more than sufficient to advance our two platform technologies with many dedicated senior executives and scientists to execute our strategic plan,” noted Mr. Tardugno. “Our development strategy and timetables remain unchanged, with two key milestones expected in the near term. We remain on track with preparations to begin a Phase 1 study with IMNN-101, which utilizes our PlaCCine technology, to generate human proof-of-concept data in a seasonal COVID-19 booster vaccine. We look forward to reporting topline data this summer from the OVATION 2 Study with IMNN-001 in advanced ovarian cancer.

 

“We wish Corinne well in her future endeavors and appreciate her contributions to the company. Meanwhile, an active search is underway for a new CEO,” said Mr. Tardugno.

 

IMUNON plans to report fourth quarter and full year 2023 financial results and hold an investment community conference call on March 28, 2024, during which management will provide a corporate update and answer questions. Additional information regarding the conference call will be announced in the coming days.

 

About IMUNON

 

IMUNON is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across four modalities. The first modality, TheraPlas®, is developed for the coding of proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a promising platform for the development of vaccines in infectious diseases. The third modality, FixPlas®, concerns the application of our DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas®, is in the discovery phase and will focus on the development of personalized cancer vaccines, or neoepitope cancer vaccines.

 

The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of newly diagnosed advanced ovarian cancer currently in Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company is conducting IND-enabling preclinical studies for the development of a COVID-19 booster vaccine (IMNN-101) and a treatment for the LASSA virus (IMNN-102). The Company has also initiated preclinical work to develop a Trp2 tumor associated antigen cancer vaccine in melanoma (IMNN-201). We will continue to leverage these modalities and to advance the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information on IMUNON, visit www.imunon.com.

 

 
 

 

Forward-Looking Statements

 

IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the Company’s transition process with respect to its Chief Executive Officer and the Company’s plans and expectations with respect to its development programs, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to transitions in the Company’s management; unforeseen changes in the course of research and development activities and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure of conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible acquisitions or licenses of other technologies, assets or businesses; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

 

Contacts:

 

IMUNON LHA Investor Relations
Jeffrey W. Church Kim Sutton Golodetz
Executive Vice President, CFO 212-838-3777
and Corporate Secretary Kgolodetz@lhai.com
609-482-2455  
jchurch@imunon.com  

 

# # #

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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imnn-20240306.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 imnn-20240306_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 imnn-20240306_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Mar. 06, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 06, 2024
Entity File Number 001-15911
Entity Registrant Name Imunon, Inc.
Entity Central Index Key 0000749647
Entity Tax Identification Number 52-1256615
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 997 Lenox Drive
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Lawrenceville
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08648-2311
City Area Code (609)
Local Phone Number 896-9100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.01 per share
Trading Symbol IMNN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

(;%BJQ"(6,P$ "(" / " 6D0 !X M;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " "GB&Q8)!Z;HJT #X 0 &@ M @ ')$0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$" M% ,4 " "GB&Q899!YDAD! #/ P $P @ &N$@ 6T-O F;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" #X$P ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://imunon.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm imnn-20240306.xsd imnn-20240306_lab.xml imnn-20240306_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "IMNN", "nsuri": "http://imunon.com/20240306", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "imnn-20240306.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "imnn-20240306_lab.xml" ] }, "presentationLink": { "local": [ "imnn-20240306_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://imunon.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://imunon.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001493152-24-009684-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-009684-xbrl.zip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end XML 17 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000749647 2024-03-06 2024-03-06 iso4217:USD shares iso4217:USD shares false 0000749647 8-K 2024-03-06 Imunon, Inc. DE 001-15911 52-1256615 997 Lenox Drive Suite 100 Lawrenceville NJ 08648-2311 (609) 896-9100 false false false false Common stock, par value $0.01 per share IMNN NASDAQ false